FDA panel backs Valeant's brodalumab with risk plan

On Tuesday, FDA's Dermatologic and Ophthalmic Drugs Advisory Committee voted unanimously to recommend approval of brodalumab ( KHK4827) from Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) to treat moderate to severe plaque

Read the full 312 word article

User Sign In